Nordic Nanovector ASA | Ownership
Companies that own Nordic Nanovector ASA
Folketrygdfondet
3,903,736
7.95%
0
0.16%
02/20/2017
BlackRock Advisors (UK) Ltd.
917,856
1.87%
2,020
0%
09/06/2018
Nordea Investment Management AB (Norway)
796,289
1.62%
796,289
0.11%
02/20/2017
KLP Kapitalforvaltning AS
684,930
1.4%
0
0.03%
08/31/2018
Max Mitteregger Kapitalförvaltning AB
300,000
0.61%
300,000
0.55%
12/31/2016
Dimensional Fund Advisors LP
250,273
0.51%
31,301
0%
04/30/2018
Storebrand Asset Management AS
244,879
0.5%
0
0.01%
08/31/2018
BlackRock Fund Advisors
207,614
0.42%
0
0%
09/06/2018
DNB Asset Management AS
159,121
0.32%
5,636
0.01%
07/31/2018
Arctic Fund Management AS
140,000
0.28%
0
0.12%
12/31/2017
| Address |
Kjelsasveien 168 B
Oslo PS 0884
Norway
|
|
Employees
|
- |
| Website |
http://www.nordicnanovector.com |
| Updated |
07/08/2019 |
| Nordic Nanovector ASA engages in the provision of development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers such as non-Hodgkin's Lymphoma and leukaemia. It offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. Nordic Nanovector operates its business through the following geographical segments: Norway, Switzerland, and the United Kingdom. |
